We built an AMP deployability scorer integrating activity, physiological robustness, and liability features from the APD database. On a standard benchmark, it achieves AUROC 0.
Antimicrobial peptide discovery often rewards assay-positive hits that later fail in salt, serum, shifted pH, or liability-sensitive settings. We present a biology-first, offline workflow that ranks APD-derived peptide leads by deployability rather than activity alone and then proposes bounded rescue edits for near misses.
Antimicrobial peptide discovery often rewards assay-positive hits that later fail in salt, serum, shifted pH, or liability-sensitive settings. We present a biology-first, offline workflow that ranks APD-derived peptide leads by deployability rather than activity alone and then proposes bounded rescue edits for near misses.
Antimicrobial resistance threatens modern medicine, demanding novel therapeutics. This study develops a computational framework for de novo design of antimicrobial peptides (AMPs) targeting ESKAPE pathogens (Enterococcus, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae) using genetic algorithm optimization.